Indivior logo

INDV - Indivior Share Price

59.35p -2.1  -3.4%

Last Trade - 27/05/20

Market Cap £450.1m
Enterprise Value £-58.4m
Revenue £567.7m
Position in Universe 518th / 1828
Bullish
Bearish
Unlock INDV Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Indivior PLC revenues decreased 36% to $153M. Net loss totaled $163M vs. income of $66M. Revenues reflect United States segment decrease of 48% to $105M. Net loss reflects Legal expenses/provision increase from $8M to $183M (expense), Selling/General/Admin. Expense, increase of 72% to $74M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from $0.09 to -$0.22.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

INDV Revenue Unlock INDV Revenue

Net Income

INDV Net Income Unlock INDV Revenue

Normalised EPS

INDV Normalised EPS Unlock INDV Revenue

PE Ratio Range

INDV PE Ratio Range Unlock INDV Revenue

Dividend Yield Range

INDV Dividend Yield Range Unlock INDV Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
INDV EPS Forecasts Unlock INDV Revenue
Profile Summary

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia. Its products are Suboxone Film (buprenorphine and naloxone), Suboxone Tablet (buprenorphine and naloxone), and Subutex Tablet (buprenorphine). Its other products include RBP-6000 in ATRIGEL, RBP-7000 risperidone monthly depot, Arbaclofen placarbil for alcohol use disorder (AUD), Intranasal naloxone for treatment of opioid overdose and RBP-8000 cocaine esterase for cocaine intoxication. Its RBP-6000 buprenorphine monthly depot is developed for the treatment of opioid use disorder. Its RBP-7000 risperidone monthly depot is developed for treatment of schizophrenia.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated September 26, 2014
Public Since December 23, 2014
No. of Shareholders: n/a
No. of Employees: 824
Sector Healthcare
Industry Pharmaceuticals
Index FTSE All Share , FTSE All Share Health Care , FTSE All Share Pharmaceuticals & Biotechnology , FTSEurofirst 300 Ex Eurozone, FTSE Smallcap , FTSE Smallcap Ex Its , ,
Exchange London Stock Exchange (Full)
Shares in Issue 732,436,173
Free Float (0.0%)
Eligible for
ISAs
SIPPs
INDV Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for INDV
Upcoming Events for INDV
Tuesday 2nd June, 2020
Indivior PLC at Jefferies Healthcare Conference (Virtual)
Wednesday 29th July, 2020 Estimate
Half Year 2020 Indivior PLC Earnings Release
Frequently Asked Questions for Indivior
What is the Indivior share price?

As of 27/05/20, shares in Indivior are trading at 59.35p, giving the company a market capitalisation of £450.1m. This share price information is delayed by 15 minutes.

How has the Indivior share price performed this year?

Shares in Indivior are currently trading at 59.35p and the price has moved by 25.36% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Indivior price has moved by 51.12% over the past year.

What are the analyst and broker recommendations for Indivior?

Of the analysts with advisory recommendations for Indivior, there are there are currently 1 "buy" , 3 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Indivior is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Indivior next release its financial results?

Indivior is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Indivior dividend yield?

Indivior does not currently pay a dividend.

Does Indivior pay a dividend?

Indivior does not currently pay a dividend.

When does Indivior next pay dividends?

Indivior does not currently pay a dividend.

How do I buy Indivior shares?

To buy shares in Indivior you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Indivior?

Shares in Indivior are currently trading at 59.35p, giving the company a market capitalisation of £450.1m.

Where are Indivior shares listed? Where are Indivior shares listed?

Here are the trading details for Indivior:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: INDV
What kind of share is Indivior?

Based on an overall assessment of its quality, value and momentum, Indivior is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Indivior share price forecast 2020?

Shares in Indivior are currently priced at 59.35p. At that level they are trading at 17.45% discount to the analyst consensus target price of 71.90.

Analysts covering Indivior currently have a consensus Earnings Per Share (EPS) forecast of -0.007 for the next financial year.

How can I tell whether the Indivior share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Indivior. Over the past six months, the relative strength of its shares against the market has been 94.06%. At the current price of 59.35p, shares in Indivior are trading at 33.83% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Indivior PE Ratio?

The Indivior PE ratio based on its reported earnings over the past 12 months is 5. The shares are currently trading at 59.35p.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Indivior?

Indivior's management team is headed by:

Howard Pien - CHM
Shaun Thaxter - CEO
Richard Simkin - OTH
Jon Fogle - CHO
Debby Betz - OTH
Mark Crossley - CFO
Javier Rodriguez - OTH
Christian Heidbreder - CSO
A. Thomas McLellan - NID
Daniel Tasse - NED
Tatjana May - NID
Peter Bains - NID
Cynthia Cetani - CCO
Graham Hetherington - NID
Rosh Dias - OTH
Who are the major shareholders of Indivior?

Here are the top five shareholders of Indivior based on the size of their shareholding:

Aberdeen Standard Investments (Edinburgh) Investment Advisor
Percentage owned: 14.48% (106.0m shares)
Scopia Capital Management LP Hedge Fund
Percentage owned: 13% (95.2m shares)
Merian Global Investors (UK) Limited Investment Advisor/Hedge Fund
Percentage owned: 7.97% (58.4m shares)
Artemis Investment Management LLP Investment Advisor/Hedge Fund
Percentage owned: 6.39% (46.8m shares)
M & G Investment Management Ltd. Investment Advisor
Percentage owned: 4.98% (36.5m shares)
Similar to INDV
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.